We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Stakeholders Ask FDA to Clarify Guidance on ‘Indications and Usage’ in Labeling
Stakeholders Ask FDA to Clarify Guidance on ‘Indications and Usage’ in Labeling
In comments on the FDA’s draft guidance on the Usage and Indication sections of drug labeling, Novartis and Pfizer asked the agency to clarify its thinking on limitations of use.